Replimune Group Amends Sales Agreement with Leerink Partners LLC

Replimune Group, Inc. (NASDAQ: REPL) recently announced changes to its Sales Agreement with Leerink Partners LLC. The amendment, dated November 25, 2024, modifies the existing agreement between the company and the agent.

Originally initiated on August 3, 2023, the Sales Agreement allowed Replimune Group the flexibility to sell shares (referred to as the “Shares”) of the company’s common stock under a prospectus through Leerink Partners LLC, in what is known as an At The Market (ATM) Offering.

With the new Amendment No. 2 to the Sales Agreement, the aggregate offering amount under the Sales Agreement has been revised. The initial $100,000,000 value of Shares has been adjusted to $89,000,000.

In light of the recent amendment, Replimune Group will temporarily halt any sales of Shares under the Sales Agreement until a new prospectus, prospectus supplement, or registration statement is filed with the Securities and Exchange Commission (SEC). Despite the adjustments, the Sales Agreement continues to remain in effect.

The Shares to be sold, if any, as per the amended Sales Agreement will be issued and marketed through methods defined as an “at the market offering” or through negotiated transactions, complying with the rules under the Securities Act of 1933, including using the previously filed Registration Statement (File No. 333-273633) and its subsequent amendments.

It is important to note that this Current Report on Form 8-K does not serve as an offer to sell or solicit an offer to buy the Shares. The sale of the Shares will not proceed in any state or jurisdiction where such transactions would be unlawful without prior registration or qualification under the respective securities laws.

The signatories and the company’s executive team have duly caused this report to be signed on November 26, 2024, with Sushil Patel serving as the current Chief Executive Officer.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Replimune Group’s 8K filing here.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.